Literature DB >> 18772645

Blood pressure control in patients with comorbidities.

Roland E Schmieder1, Luis M Ruilope.   

Abstract

Hypertension frequently coexists with obesity, diabetes, hyperlipidemia, or the metabolic syndrome; their association with cardiovascular disease is well established. The identification and management of these risk factors is an important part of the overall management of hypertensive patients. Because patients in these special populations are more predisposed to target organ damage (TOD), stringent targets for blood pressure (BP) control have been set in clinical guidelines. However, clinical trial and real-life evidence suggest that these targets are difficult to achieve. Patients with these comorbidities are more likely to require combination therapy, yet physicians are often reluctant to adjust the number and doses of medications to achieve target BP. There is a particular need for effective 24-hour BP control in these patients, due to the increased likelihood of nondipping status, which is a risk factor for TOD and mortality. Not all available antihypertensives are equally effective in controlling BP over 24 hours, and some may exacerbate underlying metabolic abnormalities.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18772645      PMCID: PMC8110138          DOI: 10.1111/j.1751-7176.2008.08172.x

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  54 in total

1.  Evaluating the impact of population and high-risk strategies for the primary prevention of cardiovascular disease.

Authors:  Jonathan Emberson; Peter Whincup; Richard Morris; Mary Walker; Shah Ebrahim
Journal:  Eur Heart J       Date:  2004-03       Impact factor: 29.983

Review 2.  Diabetes, hypertension, and cardiovascular disease: an update.

Authors:  J R Sowers; M Epstein; E D Frohlich
Journal:  Hypertension       Date:  2001-04       Impact factor: 10.190

3.  Combined effects of systolic blood pressure and serum cholesterol on cardiovascular mortality in young (<55 years) men and women.

Authors:  F Thomas; K Bean; L Guize; S Quentzel; P Argyriadis; A Benetos
Journal:  Eur Heart J       Date:  2002-04       Impact factor: 29.983

4.  Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial.

Authors:  Anushka Patel; S MacMahon; J Chalmers; B Neal; M Woodward; L Billot; S Harrap; N Poulter; M Marre; M Cooper; P Glasziou; D E Grobbee; P Hamet; S Heller; L S Liu; G Mancia; C E Mogensen; C Y Pan; A Rodgers; B Williams
Journal:  Lancet       Date:  2007-09-08       Impact factor: 79.321

5.  Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  Hypertension       Date:  2003-12-01       Impact factor: 10.190

6.  Resistant hypertension, obesity, sleep apnea, and aldosterone: theory and therapy.

Authors:  Theodore L Goodfriend; David A Calhoun
Journal:  Hypertension       Date:  2004-01-19       Impact factor: 10.190

7.  Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial.

Authors:  Stevo Julius; Sverre E Kjeldsen; Michael Weber; Hans R Brunner; Steffan Ekman; Lennart Hansson; Tsushung Hua; John Laragh; Gordon T McInnes; Lada Mitchell; Francis Plat; Anthony Schork; Beverly Smith; Alberto Zanchetti
Journal:  Lancet       Date:  2004-06-19       Impact factor: 79.321

8.  Risk-factor clustering and cardiovascular disease risk in hypertensive patients.

Authors:  Derek Weycker; Gregory A Nichols; Maureen O'Keeffe-Rosetti; John Edelsberg; Zeba M Khan; Satyin Kaura; Gerry Oster
Journal:  Am J Hypertens       Date:  2007-06       Impact factor: 2.689

9.  Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group.

Authors:  L Hansson; A Zanchetti; S G Carruthers; B Dahlöf; D Elmfeldt; S Julius; J Ménard; K H Rahn; H Wedel; S Westerling
Journal:  Lancet       Date:  1998-06-13       Impact factor: 79.321

10.  Suboptimal outcome of management of metabolic cardiovascular risk factors in Hispanic patients with essential hypertension.

Authors:  C L Laffer; F Elijovich
Journal:  Hypertension       Date:  1995-12       Impact factor: 10.190

View more
  8 in total

1.  Moderate versus intensive treatment of hypertension using amlodipine/valsartan and with the addition of hydrochlorothiazide for patients uncontrolled on angiotensin receptor blocker monotherapy: results in racial/ethnic subgroups.

Authors:  Elizabeth O Ofili; Suzanne Oparil; Thomas Giles; Bertram Pitt; Das Purkayastha; Robert Hilkert; Rita Samuel; James R Sowers
Journal:  J Am Soc Hypertens       Date:  2011-04-08

2.  Hypertension and Health-Related Quality of Life (HRQoL): Evidence from the US Hispanic Population.

Authors:  Elizabeth Riley; Jongwha Chang; Chanhyun Park; Sean Kim; Inho Song
Journal:  Clin Drug Investig       Date:  2019-09       Impact factor: 2.859

3.  Effect of cardiometabolic risk factors on hypertension management: a cross-sectional study among 28 physician practices in the United States.

Authors:  Daniel A Belletti; Christopher Zacker; Jenifer Wogen
Journal:  Cardiovasc Diabetol       Date:  2010-02-01       Impact factor: 9.951

4.  Efficacy of Single-Pill Combination of Telmisartan 80 mg and Hydrochlorothiazide 25 mg in Patients with Cardiovascular Disease Risk Factors: A Prospective Subgroup Analysis of a Randomized, Double-Blind, and Controlled Trial.

Authors:  Harold Bays; Pingjin Gao; Birgit Völker; Michaela Mattheus; Luis M Ruilope; Dingliang Zhu
Journal:  Int J Hypertens       Date:  2013-04-04       Impact factor: 2.420

5.  Relationship Between Psychosocial Stress and Blood Pressure: The National Heart, Lung, and Blood Institute Family Heart Study.

Authors:  Uzoji Nwanaji-Enwerem; Elijah O Onsomu; Dionne Roberts; Abanish Singh; Beverly H Brummett; Redford B Williams; Jennifer R Dungan
Journal:  SAGE Open Nurs       Date:  2022-06-23

6.  Uncontrolled blood pressure and contributing factors among patients with hypertension at outpatient care of Bedele General Hospital, Southwest Ethiopia: A cross-sectional study.

Authors:  Tadesse Sheleme; Oda Jilo; Firomsa Bekele; Wayessa Olika; Birbirsa Safera; Yadeta Babu
Journal:  SAGE Open Med       Date:  2022-09-26

7.  Olmesartan/amlodipine/hydrochlorothiazide in participants with hypertension and diabetes, chronic kidney disease, or chronic cardiovascular disease: a subanalysis of the multicenter, randomized, double-blind, parallel-group TRINITY study.

Authors:  Dean J Kereiakes; Steven G Chrysant; Joseph L Izzo; Thomas Littlejohn; Michael Melino; James Lee; Victor Fernandez; Reinilde Heyrman
Journal:  Cardiovasc Diabetol       Date:  2012-10-30       Impact factor: 9.951

8.  Controlled Blood Pressure in Iranian Patients: A Multi-Center Report.

Authors:  Ezzatollah Sadeghi; Azin Behnood-Rod; Hossein Aerab-Sheibani; Elham Shobeiri; Pirouz Pourzargar; Ehsan Ormoz; Nader Sadigh; Yashar Moharamzad
Journal:  Glob J Health Sci       Date:  2015-08-19
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.